Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Nutr Metab Cardiovasc Dis ; 28(6): 582-591, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29691148

RESUMEN

BACKGROUND AND AIMS: Angiotensin receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEI) reduce cardiovascular events in the general population. Maintenance hemodialysis (MHD) patients are at high cardiovascular risk but few studies have directly addressed the comparative efficacy of these drugs. MHD disrupts the normally atheroprotective actions of high density lipoprotein (HDL), therefore, we compared ACEI or ARB treatment on HDL functions in MHD. METHODS AND RESULTS: HDL was isolated at the starting point (pre) and 3-6 months later (post) in 30 MHD randomly assigned to placebo, ramipril or valsartan. Outcomes included cholesterol efflux, inflammatory cytokine response, effects on Toll-like receptors (TLR), superoxide production, methylarginine and serum amyloid A (SAA) levels. HDL from ARB- or ACEI-treated subjects was more effective in maintaining efflux than HDL of placebo. HDL from ARB- or ACEI-treated subjects but not placebo lessened cellular superoxide production. In contrast, neither ARB nor ACEI improved HDL anti-inflammatory effect. Indeed, HDL of ACEI-treated subjects potentiated the cytokine responses in association with activation of TLR but did not alter the HDL content of methylarginines or SAA. CONCLUSION: Both ACEI and ARB stabilized HDL cholesterol acceptor function and sustained cellular anti-oxidative effects but not anti-inflammatory effects, and ACEI-treatment instead amplified the HDL inflammatory response. The findings reveal possible utility of antagonizing angiotensin actions in MDH and suggest a possible mechanism for superiority of ARB vs ACEI in the setting of advanced kidney disease.


Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , HDL-Colesterol/sangre , Fallo Renal Crónico/terapia , Ramipril/uso terapéutico , Diálisis Renal , Valsartán/uso terapéutico , Adulto , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Biomarcadores/sangre , Método Doble Ciego , Femenino , Humanos , Mediadores de Inflamación/sangre , Fallo Renal Crónico/sangre , Fallo Renal Crónico/diagnóstico , Masculino , Persona de Mediana Edad , Estrés Oxidativo/efectos de los fármacos , Ramipril/efectos adversos , Diálisis Renal/efectos adversos , Tennessee , Factores de Tiempo , Resultado del Tratamiento , Valsartán/efectos adversos
2.
Neurology ; 62(9): 1601-3, 2004 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-15136690

RESUMEN

We report of a woman aged 52 years born to consanguineous parents and seeking treatment for progressive dementia and delusion. Neurologic examination revealed dementia and emotional instability, indifference, and confabulation. There was also mild spasticity of the bilateral lower limbs. MRI revealed diffuse white matter hyperintensity on T2-weighted images accompanied by hypointense areas on fluid-attenuated inversion recovery images. A homozygous missense mutation was identified in EIF2B5.


Asunto(s)
Enfermedades Desmielinizantes/genética , Factor 2B Eucariótico de Iniciación/genética , Mutación Missense/genética , Adulto , Edad de Inicio , Encéfalo/metabolismo , Encéfalo/patología , Creatina/metabolismo , Análisis Mutacional de ADN , Enfermedades Desmielinizantes/diagnóstico , Enfermedades Desmielinizantes/metabolismo , Femenino , Humanos , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Persona de Mediana Edad , Fosfocreatina/metabolismo , Análisis de Secuencia de ADN
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA